Mr. Moyes has 30 years of management and leadership experience. He was instrumental in the financial development and expansion of Myriad Genetics and currently sits on the board for Osiris Therapeutics, Bicardia, Integrated Diagnostics and Puma Biotechnology.
More Articles on Orthopedic Devices:
Globus Medical 3Q Worldwide Sales Reach $94.8M, Up 12.5%
X-spine Announces FDA Approval for 2 Spine Systems
Zimmer Pulls Metal-on-Metal Hip Device From Australia
Amedica Names Jay Moyes to Board of Directors
Amedica has named Jay M. Moyes to its board of directors.
Staying ahead of OBBBA: Tools and strategies to protect patients and strengthen RCM
Recommended Whitepaper